Bay Street News, 2018

Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in […]

Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, […]

CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing […]

ANCHORAGE, Ala., Dec. 01, 2018 (GLOBE NEWSWIRE) — For our customers impacted by the earthquake that struck Alaska on November […]

Company to Host Investor Meeting and Webcast on Monday, December 3, at 8 pm PST CAMBRIDGE, Mass. and BEIJING, China, […]

In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r […]

Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was […]

NEW YORK, Dec. 01, 2018 (GLOBE NEWSWIRE) — Nasdaq announces that it will observe the passing of President George H.W. […]

— 29.6% Overall Response Rate Including 9.6% Complete Response Rate — — Amongst the Patients with Complete or Partial Response, Median Duration […]

Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for […]